|
Lip GY, Durrani OM, Roldan V, Lip PL, Marin F, Reuser TQ. Peri-operative management of ophthalmic patients taking antithrombotic therapy. Int J Clin Pract. 2011 Mar;65(3):361-71. doi: 10.1111/j.1742-1241.2010.02538.x. Review. PubMed PMID: 21314873.
AÑO: 2011; IF: 2.415
|
21314873
|
Vílchez J., Hernández-Romero D., Ruiz-Espejo F., Garcia-Honrubia A., Valdés M., Martínez-Hernández P., Marín F. Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy. Clinical Chemistry and Laboratory Medicine. 1 September 2011. 49:1569-1571. 10.1515/CCLM.2011.642
AÑO: 2011; IF: 2.15
|
|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|
|
Lip G.Y.H., Andreotti F., Fauchier L., Huber K., Hylek E., Knight E., Lane D.A., Levi M., Marin F., Palareti G., Kirchhof P., Collet J.P., Rubboli A., Poli D., Camm J. Bleeding risk assessment and management in atrial fibrillation patients: A position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. May 2011. 13:723-746. 10.1093/europace/eur126
AÑO: 2011; IF: 1.98
|
|
Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F. Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):521-30. doi: 10.1177/1470320311405247. Epub 2011 Apr 20. Review. PubMed PMID: 21507890.
AÑO: 2011; IF: 2.439
|